12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers

• Reneo Pharmaceuticals RPHM shares increased by 6.4% to $6.82 during Wednesday's after-market session. The company's market cap stands at $166.5 million.
• Galapagos GLPG stock moved upwards by 5.02% to $56.0. The company's market cap stands at $3.6 billion.
• PetVivo Holdings PETV shares increased by 5.0% to $2.1. The company's market cap stands at $20.4 million.
• Sierra Oncology SRRA stock rose 4.74% to $30.0. Sierra Oncology's trading volume hit 378.9K shares by close, accounting for 64.2% of its average volume over the last 100 days. The company's market cap stands at $451.6 million.
• Hepion Pharmaceuticals HEPA stock rose 3.6% to $1.01. The market value of their outstanding shares is at $76.9 million.
• Revance Therapeutics RVNC shares increased by 3.53% to $13.17. The company's market cap stands at $945.5 million.

Losers

• Epizyme EPZM stock fell 18.4% to $1.55 during Wednesday's after-market session. This security traded at a volume of 52.8K shares come close, making up 3.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $161.0 million.
• Accuray ARAY stock fell 16.47% to $3.4. The company's market cap stands at $309.1 million. As per the press release, Q2 earnings came out today.
• Zymeworks ZYME stock declined by 11.19% to $8.26. The market value of their outstanding shares is at $384.5 million.
• Avinger AVGR stock declined by 5.09% to $0.28. The market value of their outstanding shares is at $26.7 million.
• Edwards Lifesciences EW stock decreased by 5.03% to $103.18. At the close, Edwards Lifesciences's trading volume reached 433.5K shares. This is 17.7% of its average volume over the last 100 days. The company's market cap stands at $64.4 billion. As per the press release, Q4 earnings came out today.
• AquaBounty Technologies AQB shares declined by 4.77% to $1.6. The company's market cap stands at $113.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.